1. Agren H, Lundqvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 1984;9:233–248.

2. Altemus M, Pigott T, L'Heureux F, Davis CL, Rubinow DR, Murphy DL, Gold PW. CSF somatostatin in obsessive-compulsive disorder. Am J Psychiatry 1993;150:460–464.

3. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic–pituitary–adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990;13:257–261.

4. Argente J, Chowen-Breed JA, Steiner RA, Clifton DK. Somatostatin messenger RNA in hypothalamic neurons is increased by testosterone through activation of androgen receptors and not by aromatization to estradiol. Neuroendocrinology 1990;52:342–349.

5. Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, Martin JB. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol 1988;23:562–569.

6. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34–38.

7. Benyassi A, Tapia-Arancibia L, Arancibia S. Glutamate peripherally administered exerts somatostatin-releasing actionin the conscious rat. J Neuroendocrinol 1991;3:429–432.

8. Bissette G, Widerlov E, Walleus H, Karlsson I, Eklund K, Forsman A, Nemeroff CB. Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders. Arch Gen Psychiatry 1986;43:1148–1151.

9. Bowen DM, Najlerahim A, Procter AW, Francis PT, Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci USA 1989;86:9504–9508.

10. Breder CD, Yamada Y, Yasuda K, Seino S, Saper CB, Bell GI. Differential expression of somatostatin receptors subtypes in brain. J Neurosci 1992;12:3920–3934.

11. Candy JM, Gascoigne AD, Biggins A, et al. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease. J Neurol Sci 1985;71:315–323.

12. Charlton BG, Leake A, Wright C, Fairbairn AF, McKeith IG, Candy JM, Ferrier IN. Somatostatin content and receptors in the cerebral cortex of depressed and control subjects. J Neurol Neurosurg Psychiatry 1988;51:719–721.

13. Charlton BG, Wright C, Leake A, Ferrier IN, Cheetham SC, Horton RW, Crompton MR. Somatostatin immunoreactivity in postmortem brain from depressed suicides [Letter]. Arch Gen Psychiatry 1988;45:597.

14. Cottrell GA, Robertson HA. Prevention of cysteamine-induced myoclonus blocks the long-term inhibition of kindled seizures. Brain Res 1987;412:161–164.

15. Doran AR, Rubinow DR, Wolkowitz OM, Roy A, Breier A, Pickar D. Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA. Biol Psychiatry 1989;25:431–439.

16. Epelbaum J. Somatostatin receptors in the central nervous system. In: Weil C, Muller EE, Thorner MO, eds. Somatostatin: basic and clinical aspects of neuroscience, vol 4. Berlin: Springer-Verlag, 1992;17–28.

17. Ferrier IN, McKeith IG, Charlton BG, et al. Postmortem investigations of serotonergic and peptidergic hypotheses of affective illness. In: Lerer B, Gershon S, eds. New directions in affective disorders. New York: Springer-Verlag, 1989;60–63.

18. Gattaz WF, Rissler K, Gattaz D, Cramer H. Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of schizophrenic patients. Psychiatry Res 1986;17:1–6.

19. Gomez S, Davous P, Rondot P, Faivre-Bauman A, Valade D, Puymirat J. Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type. Psychoneuroendocrinology 1986;11:69–73.

20. Goodman RH, Rehfuss RP, Verhave M, Ventimiglia R, Low MJ. Somatostatin gene regulation: an overview. Metabolism 1990;39 (Suppl 2):2–5.

21. Kakigi T, Maeda K. Effect of serotonergic agents on regional concentrations of somatostatin- and neuropeptide Y-like immunoreactivities in rat brain. Brain Res 1992;599:45–50.

22. Kakigi T, Maeda K, Kaneda H, Chihara K. Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J Affective Disord 1992;25:215–220.

23. Kaye WH, Rubinow DR, Gwirtsman HE, George DT, Jimerson DC, Gold PW. CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic pituitary–adrenal cortical axis. Psychoneuroendocrinology 1988;13:265–272.

24. Kleuss C, Hescheler J, Ewel C, Rosenthal W, Schultz G, Wittig B. Assignment of G protein subtypes to specific receptors inducing inhibition of calcium currents. Nature 1991;353:43–48.

25. Kling MA, Rubinow DR, Doran AR, et al. Cerebrospinal fluid somatostatin immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 1993;57:79–88.

26. Kruesi MJP, Swedo S, Leonard H, Rubinow DR, Rapoport JL. CSF somatostatin in childhood psychiatric disorders: a preliminary investigation. Psychiatry Res 1990;33:277–284.

27. Kupfer DJ, Jarrett DB, Ehlers CL. The effect of SRIF on the EEG sleep of normal men. Psychoneuroendocrinology 1992;17:37–43.

28. Lahtinen H, Pitkanen A, Tuomisto L, Riekkinen P. Effect of antiepileptic drugs on somatostatin release in vitro. Neuropeptides 1990;17:29–34.

29. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 1988;111:785–799.

30. Martin JL, Chesselet MF, Raynor K, Gonzales C, Reisine T. Differential distribution of somatostatin receptor subtypes in rat brain revealed by newly developed somatostatin analogs. Neuroscience 1991;41:581–593.

31. Matsuoka N, Kaneko S, Satoh M. Somatostatin augments long-term potentiation of the mossy fiber–CA3 system in guinea pig hippocampal slices. Brain Res 1991;553:188–194.

32. McCann SM. Physiology and pharmacology of LHRH and somatostatin. Annu Rev Pharmacol Toxicol 1982;22:491–515.

33. Molchan SE, Lawlor BA, Hill JL, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991;29:1110–1118.

34. Monno A, Rizzi M, Samanin R, Vazzani A. Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats. Brain Res 1993;602:148–152.

35. Patel YC. General aspects of the biology and function of somatostatin. In: Weil C, Muller EE, Thorner MO, eds. Basic and clinical aspects of neuroscience, vol 4. Berlin: Springer-Verlag, 1992;1–16.

36. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990;39(Suppl 2):63–69.

37. Patel YC, Rao K, Reichlin S. Somatostatin in human cerebrospinal fluid. N Engl J Med 1977;296:529–533.

38. Patel YC, Srikant CB. Somatostatin mediation of adenohypophysial secretion. Annu Rev Physiol 1985;48:551–567.

39. Perez-Oso E, Lopez-Ruiz MP, Arilla E. Effect of haloperidol withdrawal on somatostatin level and binding in rat brain. Biosci Rep 1990;10:15–22.

40. Pitkanen A, Jolkkonen J, Riekkinen P. b-endorphin, somatostatin, and prolactin levels in cerebrospinal fluid of epileptic patients after generalised convulsion. J Neurol Neurosurg Psychiatry 1987;50: 1294–1297.

41. Post RM, Ballenger JC, Uhde TW, Bunney WE. Efficacy of carbamazepine in manic–depressive illness: implications for underlying mechanisms. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984;777–816.

42. Qin Y, Soghomonian J, Chesselet M. Effects of quinolinic acid on messenger RNAs encoding somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Exp Neurol 1992;115:200–211.

43. Rissler K, Cramer H, Schaudt D, Strubel D, Gattaz WF. Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease. Neurosci Res 1986;3:213–225.

44. Robbins RJ. Regulation of hypothalamic somatostatin secretion. In: Reichlin S, ed. Somatostatin: basic and clinical status. New York: Plenum Press, 1987;149–156.

45. Robbins RJ, Brines ML, Kim JH, et al. A selective loss of somatostatin in the hippocampus of patients with temporal lobe epilepsy. Ann Neurol 1991;29:325–332.

46. Rosler N, Reuner C, Geiger J, Rissler K, Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides 1990;11:181–183.

47. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986;21:341–365.

48. Rubinow DR, Davis CL, Post RM. Somatostatin in neuropsychiatric disorders. In: Weil C, Muller EE, Thorner MO, eds. Somatostatin: basic and clinical aspects of neuroscience, vol 4. Berlin: Springer-Verlag, 1992;29–42.

49. Scharfman HE, Schwartzkroin PA. Selective depression of GABA-mediated IPSPs by somatostatin in area CA1 of rabbit hippocampal slices. Brain Res 1989;493:205–211.

50. Shinoda H, Nadi NS, Schwartz JP. Alterations in somatostatin and proenkephalin mRNA in response to a single amygdaloid stimulation versus kindling. Mol Brain Res 1991;11:221–226.

51. Sorensen KV, Christensen SE, Dupont E, Hansen AP, Pedersen E, Orskov H. Low somatostatin content in cerebrospinal fluid in multiple sclerosis. Acta Neurol Scand 1980;61:186–191.

52. Sperk G, Marksteiner J, Gruber B, Bellmann R, Mahata M, Ortler M. Functional changes in neuropeptide Y- and somatostatin- containing neurons induced by limbic seizures in the rat. Neuroscience 1992;50:831–846.

53. Su T, Hauser P, Rubinow DR, et al. CSF somatostatin (SRIF), mood, and cognition in multiple sclerosis. In: Abstracts of the twenty-first congress of the ISPNE, 1990;81.

54. Tahiri-Jouti N, Cambillau C, Viguerie N, Vidal C, Saint Laurent N, Vaysse N, Susini C. Characterization of a membrane tyrosine phosphatase in AR42J cells: regulation by somatostatin. Am J Physiol 1992;262:G1007–G1014.

55. Tallent M, Reisine T. Gi alpha 1 selectively couples somatostatin receptors to adenylyl cyclase in pituitary-derived AtT-20 cells. Mol Pharmacol 1992;41:452–455.

56. Traskman-Bendz L, Ekman R, Regnell G, Ohman R. HPA-related CSF neuropeptides in suicide attempts. Eur Neuropsychopharmacol 1992;2:99–106.

57. Vecsei L, Widerlov E. Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness: an overview. Acta Psychiatr Scand 1988;78:657.

58. Vecsei L, Widerlov E. Effects of somatostatin-28 and some of its fragments and analogs on open-field behavior, barrel rotation, and shuttle box learning in rats. Psychoneuroendocrinology 1990;15: 139–145.

59. Vezzani A, Serafini R, Stasi MA, Vigano G, Rizzi M, Samanin R. A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201-995) modulates seizures induced by quinolinic and kainic acids differentially in the rat hippocampus. Neuropharmacology 1991;30:345–352.

60. Walsh TJ, Emerich DF, Winokur A, Banki C, Bissette G, Nemeroff CB. Intrahippocampal injection of cysteamine depletes somatostatin and produces cognitive impairments in the rat. Neurosci Abstr 1985;11:621.

61. Weckbecker G, Tolcsvai L, Liu R, Bruns C. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 1992;41(Suppl 2):99–103.

62. Xie Z, Sastry BR. Actions of somatostatin on GABA-ergic synaptic transmission in the CA1 area of the hippocampus. Brain Res 1992;591:239–247.

63. Yasuda K, Espinosa R III, Davis EM, LeBeau MM, Bell GI. Human somatostatin receptor genes: localization of SSTR5 to human chromosome 20p11.2. Genomics 1993;17:785–786.

64. Zorrilla R, Simard J, Rheaume E, Labrie F, Pelletier G. Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. Neuroendocrinology 1990;52:527–536.